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Phenotype characterization of Mtor-cKO mice — Mtor-cKO mice develop 























Characterization of Mtor-cKO mice. (A) Kaplan-Meier survival curves of Mtor-cKO and control (CTL) mice. Mortality of Mtor-cKO mice begins 
4 weeks after TMX administration and reaches 100% by 8 weeks. Time is shown as weeks after TMX administration (n = 11 for Mtor-cKO mice; 
n = 7 for TMX-injected Mtorfl/fl mice [F/F] control; n = 6 for WT-Cre control). (B) Representative explanted hearts. The Mtor-cKO heart is larger 
than that of controls. (C) Representative H&E-stained heart sections. Mtor-cKO hearts have thinned ventricular walls and enlarged cardiac 
chambers. (D) Dobutamine stress test, at 4 weeks after TMX administration, of Mtor-cKO (KO) and WT-Cre control hearts. Mtor-cKO hearts 
have greatly hampered basal inotropy and lusitropy and have only a very weak reactivity to stimulation with increasing units of dobutamine (Dob) 
(mean ± SD; n = 7 per group). (E) Incorporation of [3H]leucine in cultured adult cardiomyocytes (mean ± SD; n = 3). (F) Fluorescence micrographs 
of heart tissue were analyzed to obtain cross-sectional cell area (mean ± SD). Cardiomyocytes become significantly and progressively smaller 
after the administration of TMX. (G) Expression of cardiac fetal genes (Nppa, encoding atrial natriuretic factor; Myh7, encoding β-myosin heavy 
chain; Acta1, encoding α1-skeletal actin), assayed by qRT-PCR and normalized for Gapdh expression, is given as fold change. Mtor-cKO 
hearts have a 2- to 8-fold increase in the expression of these genes with respect to controls at 2 weeks and 4 weeks after TMX administration, 
respectively (mean ± SD, n = 3–4 per group).
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Cell death and fibrosis are enhanced, and mitochondria 










































Echocardiographic measurements of Mtor-cKO and control mice lines
Parameter	 Wk	after	TMX		 WT-Cre	 F/F	 Mtor-cKO
	 administration
HR (bpm) 0 535 ± 67 529 ± 45 569 ± 63
HR (bpm) 1 507 ± 50 529 ± 66 554 ± 50
HR (bpm) 2 512 ± 47 578 ± 47 561 ± 59
HR (bpm) 4 545 ± 21 572 ± 70 566 ± 52
IVSd (mm) 0 0.59 ± 0.02 0.62 ± 0.03 0.61 ± 0.04
IVSd (mm) 1 0.60 ± 0.02 0.61 ± 0.03 0.61 ± 0.03
IVSd (mm) 2 0.61 ± 0.05 0.61 ± 0.03 0.6 ± 0.03
IVSd (mm) 4 0.57 ± 0.21 0.61 ± 0.04 0.54 ± 0.03A
IVSs (mm) 0 0.96 ± 0.07 1.07 ± 0.07 1.05 ± 0.13
IVSs (mm) 1 0.98 ± 0.06 1.11 ± 0.07 1.13 ± 0.09
IVSs (mm) 2 1.01 ± 0.08 1.02 ± 0.06 1.05 ± 0.07
IVSs (mm) 4 1.00 ± 0.05 1.03 ± 0.07 0.84 ± 0.10A
LVPWd (mm) 0 0.61 ± 0.03 0.62 ± 0.04 0.62 ± 0.04
LVPWd (mm) 1 0.60 ± 0.01 0.61 ± 0.03 0.62 ± 0.03
LVPWd (mm) 2 0.59 ± 0.04 0.60 ± 0.04 0.59 ± 0.03
LVPWd (mm) 4 0.60 ± 0.02 0.61 ± 0.03 0.55 ± 0.03A
LVPWs (mm) 0 1.05 ± 0.09 1.20 ± 0.09 1.17 ± 0.11
LVPWs (mm) 1 1.14 ± 0.07 1.21 ± 0.07 1.18 ± 0.11
LVPWs (mm) 2 1.13 ± 0.09 1.14 ± 0.08 1.18 ± 0.13
LVPWs (mm) 4 1.09 ± 0.09 1.15 ± 0.07 0.89 ± 0.13A
LVIDd (mm) 0 3.31 ± 0.12 3.59 ± 0.24 3.36 ± 0.44
LVIDd (mm) 1 3.42 ± 0.37 3.75 ± 0.41 3.61 ± 0.29
LVIDd (mm) 2 3.21 ± 0.27 3.41 ± 0.25 3.24 ± 0.28
LVIDd (mm) 4 2.86 ± 0.28 3.51 ± 0.46 4.06 ± 0.37A
LVIDs (mm) 0 1.65 ± 0.21 1.9 ± 0.36 1.73 ± 0.37
LVIDs (mm) 1 1.76 ± 0.35 1.92 ± 0.48 2.00 ± 0.22
LVIDs (mm) 2 1.81 ± 0.31 1.73 ± 0.24 1.71 ± 0.25
LVIDs (mm) 4 1.47 ± 0.26 1.83 ± 0.36 3.09 ± 0.51A
LVFS (%) 0 47.3 ± 5.6 47.3 ± 7.4 46.1 ± 7.7
LVFS (%) 1 45.5 ± 5.8 49.3 ± 8.4 44.6 ± 3.8
LVFS (%) 2 47.2 ± 6.4 49.4 ± 5.5 46.7 ± 8.8
LVFS (%) 4 49.2 ± 5.2 46.8 ± 5.5 26.4 ± 6.7A
HR, heart rate; IVSd, intraventricular septal thickness in diastole; IVSs, intraventricular 
septal thickness in systole; LVPWd, LV posterior wall thickness in diastole; LVPWs, LV 
posterior wall thickness in systole; LVIDd, LV internal diameter in diastole; LVIDs, LV 
internal diameter in systole; LVFS, LV fractional shortening. n = 6 mice assessed in the 
WT-Cre control group, n = 9 mice assessed in the F/F control group, and n = 9 mice 
assessed in the Mtor-cKO group. Measurements are given as mean ± SD. AP < 0.05 
versus control groups.
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Analysis of cell death. (A) Image analysis of TUNEL-stained sections revealed that the Mtor-cKO heart is subjected to a progressive loss of 
cardiomyocytes because of the induction of apoptosis (mean ± SD; n = 3 per group). (B) Representative Western blot for cleaved (clv) Parp. 
Cleaved Parp expression is increased in the heart of Mtor-cKO mice with respect to WT-Cre control littermates at 4 weeks after TMX adminis-
tration. α-Tubulin was used as an internal loading control. (C) Western blot for CoxIV expression (top). Gapdh was used as an internal loading 
control. Densitometric analysis of CoxIV expression (mean ± SD) in extracts from WT-Cre controls at 4 weeks after TMX administration and 
from Mtor-cKO mice at 1, 2, and 4 weeks after TMX administration (bottom). (D) Representative transmission electron micrographs of Mtor-cKO 
and WT-Cre control hearts, both at 2 weeks after TMX administration. Mtor-cKO LV myocardium presents with sarcomeric disarray and swollen 
mitochondria (arrowheads), whereas that of control has a normal ultrastructure. Original magnification: ×2,000. (E) Image analysis reveals that 
the fibrotic index of the Mtor-cKO heart is increased already at 1 week after TMX administration and becomes significantly increased thereafter 
(mean ± SD, n = 3 per group). (F) Western blot of some autophagy-related proteins. Expression of the 4 proteins analyzed is increased in the 
Mtor-cKO heart with respect to that of the WT-Cre control at 1 week after TMX administration. (G) Representative transmission electron micro-
graphs of WT-Cre control and Mtor-cKO heart, both at 1 week after TMX administration. Autophagic bodies (arrowheads) were observed in 
Mtor-cKO myocardium. Original magnification: ×4,000; inset, ×2,000.
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Figure 
Western blot analysis of MTORC1- and MTORC2-associated proteins. (A) Blots of 
total and phosphorylated (p) MTORC1-associated proteins from myocardial extracts 
from WT-Cre controls at 4 weeks after TMX administration (post-TMX) and from 
Mtor-cKO mice at 1, 2, and 4 weeks after TMX administration (above). Densitometry 
(arbitrary units, mean ± SD) of nonphosphorylated and total 4E-BP1 and S6 pro-
tein phosphorylated at Ser240 (below). Phosphorylation of downstream targets of 
MTORC1 is reduced by 2 weeks after TMX administration. Accumulation of 4E-BP1 
is a striking characteristic of myocardium lacking Mtor expression. Gapdh was used 
as an internal loading control. (B) Blots of total and phosphorylated MTORC2-associ-
ated proteins and of Foxo proteins in myocardial extracts from WT-Cre controls at 
4 weeks after TMX administration and from Mtor-cKO mice at 1, 2, and 4 weeks after 
TMX administration (top). Phosphorylation of Akt at sites independent of MTORC2 
(Thr308 and Thr450) was also analyzed. Densitometry (arbitrary units, mean ± SD) of 
phosphorylation levels of Akt (bottom). (C) Representative blot of myocardial extracts 
from sham- and TAC-operated wild-type mice. The MTORC1 downstream proteins S6 
kinase and S6 become less expressed when hearts are failing (8 weeks after TAC). 
Note the accumulation of 4E-BP1 bound to eIF4E at 8 weeks in TAC-operated mice. 
(D) Representative blot of myocardial extracts from wild-type littermates and MLP-KO 
mice, a genetic model of dilated cardiomyopathy. Similarly to Mtor-cKO (A) and failing 
pressure-overloaded wild-type myocardium (C), 4E-BP1 becomes dephosphorylated 
at Ser65 and more bound to eIF4E also in this model.
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Echocardiographic measurements of Mtor-cKO and control mice before TAC and 2 weeks after TAC
Parameter	 No	TAC	 TMX	(3	weeks)	
	 –	 TMX	(1	week)	 Sham	 TAC
	 WT-Cre	 Mtor-cKO	 WT-Cre	 Mtor-cKO	 WT-Cre	 Mtor-cKO	 WT-Cre	 Mtor-cKO
HR (bpm) 530 ± 44 540 ± 51 574 ± 66 554 ± 52 578 ± 47 561 ± 56 600 ± 27 571 ± 44
IVSd (mm) 0.62 ± 0.02 0.62 ± 0.04 0.63 ± 0.03 0.61 ± 0.02 0.62 ± 0.04 0.60 ± 0.03 0.89 ± 0.10A 0.70 ± 0.11
IVSs (mm) 1.09 ± 0.07 1.05 ± 0.03 1.14 ± 0.09 1.10 ± 0.07 1.02 ± 0.08 1.03 ± 0.03 1.37 ± 0.09A 1.15 ± 0.20
LVPWd (mm) 0.61 ± 0.03 0.64 ± 0.04 0.61 ± 0.01 0.62 ± 0.02 0.60 ± 0.04 0.59 ± 0.02 0.93 ± 0.10A 0.72 ± 0.12B
LVPWs (mm) 1.23 ± 0.07 1.22 ± 0.13 1.19 ± 0.04 1.16 ± 0.13 1.13 ± 0.07 1.20 ± 0.08 1.36 ± 0.15 1.24 ± 0.23
LVIDd (mm) 3.75 ± 0.17 3.38 ± 0.17 3.39 ± 0.24 3.61 ± 0.33 3.41 ± 0.31 3.24 ± 0.14 2.96 ± 0.42 3.78 ± 0.50B
LVIDs (mm) 2.02 ± 0.4 1.66 ± 0.24 1.61 ± 0.2 1.96 ± 0.26 1.74 ± 0.28 1.70 ± 0.31 1.44 ± 0.27 2.48 ± 0.73B
LVFS (%) 47.3 ± 7.3 48.1 ± 6.0 49.4 ± 8.9 47.0 ± 4.0 49.5 ± 7.0 46.7 ± 9.2 51.0 ± 8.6 35.5 ± 10.3B,C
The “–” symbol indicates mice not administered TMX. n = 5 WT-Cre and Mtor-cKO mice not subjected to TAC/sham, n = 12 WT-Cre and Mtor-cKO mice 
subjected to TAC/sham. Measurements are given as mean ± SD. AP < 0.05 versus WT-Cre sham mice; BP < 0.05 versus WT-Cre TAC mice; CP < 0.05 
versus Mtor-cKO sham mice.
Figure 
Pressure overload stress in Mtor-cKO mice. (A) qRT-PCR analysis for cardiac fetal gene expression, normalized for Gapdh, involved in the 
response to TAC in WT-Cre control and Mtor-cKO hearts. After 3 weeks of TAC (4 weeks after TMX administration for both), there is only a 
moderate increase in the expression of these genes in Mtor-cKO hearts with respect to the similarly treated control group (mean ± SD, n = 3–4 
per group). (B) Representative Western blots of TAC-operated WT-Cre and Mtor-cKO hearts, 3 weeks after the surgery.
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As a whole,  these data  suggest  that MTOR, and  in particular 
MTORC1, plays an essential role in the response of the heart to stress 
by preserving cardiac function through the induction of hypertrophy.













Survival of Mtor-cKO mice is improved 
by deletion of Eif4ebp1, and hypophos-
phorylated 4E-BP1 promotes apoptosis 
in cardiomyocytes. (A) Representative 
Western blots, at 4 weeks after TMX 
administration, of WT-Cre, Mtor-cKO, 
4E-BP1-KO, and Mtor/4E-BP1 dKO 
mouse heart lysates. (B) Kaplan-Meier 
survival curves of Mtor/4E-BP1 dKO 
(n = 13), Mtor-cKO (n = 10), and WT-
Cre mice (n = 9). Survival of Mtor/4E-
BP1 dKO mice is significantly better 
than that of Mtor-cKO mice. (C) Rep-
resentative Western blots demonstrat-
ing progressive increase of cleaved 
caspase 3 (Casp3) and caspase 9 in 
lysates obtained from cultured neo-
natal cardiomyocytes after 24-hour 
infection with adenovirus carrying a 
mutated (hypophosphorylated) form of 
4E-BP1 (4E-BP1-5A). V, empty vec-
tor; M, transgene-carrying vector; HA, 
hemagglutinin tag; Tub, α-tubulin. (D) 
Immunofluorescence of infected car-
diomyocytes. Green indicates cleaved 
caspase 3; red indicates α-actinin; blue 
indicates Hoechst staining of nuclei. 
Original magnification: ×20 (rows 1 and 
3); ×40 (rows 2 and 4).
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Expression of constitutively hypophosphory-

















































Echocardiographic measurements of the various mouse lines used in the study
Parameter	 Wk	after	TMX		 WT-Cre	 Mtor-cKO	 4EBP1-KO	 dKO
	 administration
HR (bpm) 0 540 ± 68 569 ± 59 563 ± 54 529 ± 73
HR (bpm) 1 576 ± 90 554 ± 56 567 ± 38 551 ± 53
HR (bpm) 2 600 ± 62 561 ± 56 598 ± 53 613 ± 35
HR (bpm) 4 606 ± 47 566 ± 52 622 ± 29 609 ± 66
IVSd (mm) 0 0.61 ± 0.03 0.63 ± 0.04 0.58 ± 0.03 0.58 ± 0.03
IVSd (mm) 1 0.61 ± 0.03 0.62 ± 0.02 0.55 ± 0.02 0.58 ± 0.04
IVSd (mm) 2 0.62 ± 0.03 0.60 ± 0.02 0.61 ± 0.02 0.6 ± 0.02
IVSd (mm) 4 0.61 ± 0.03 0.55 ± 0.03A 0.61 ± 0.02 0.62 ± 0.03B
IVSs (mm) 0 1.05 ± 0.06 1.04 ± 0.11 0.98 ± 0.05 0.99 ± 0.09
IVSs (mm) 1 1.07 ± 0.09 1.12 ± 0.09 0.96 ± 0.06 1.05 ± 0.06
IVSs (mm) 2 1.04 ± 0.06 1.04 ± 0.08 1.04 ± 0.04 1.01 ± 0.06
IVSs (mm) 4 1.04 ± 0.07 0.88 ± 0.12A 1.04 ± 0.05 1.09 ± 0.05
LVPWd (mm) 0 0.62 ± 0.03 0.62 ± 0.04 0.58 ± 0.02 0.56 ± 0.03
LVPWd (mm) 1 0.60 ± 0.04 0.62 ± 0.03 0.54 ± 0.02 0.59 ± 0.02
LVPWd (mm) 2 0.61 ± 0.04 0.59 ± 0.03 0.60 ± 0.03 0.60 ± 0.01
LVPWd (mm) 4 0.60 ± 0.03 0.55 ± 0.03A 0.61 ± 0.02 0.62 ± 0.03B
LVPWs (mm) 0 1.18 ± 0.10 1.17 ± 0.10 1.10 ± 0.11 1.07 ± 0.08
LVPWs (mm) 1 1.18 ± 0.07 1.18 ± 0.10 1.07 ± 0.09 1.18 ± 0.09
LVPWs (mm) 2 1.14 ± 0.07 1.16 ± 0.14 1.18 ± 0.11 1.13 ± 0.10
LVPWs (mm) 4 1.16 ± 0.08 0.92 ± 0.14A 1.19 ± 0.09 1.27 ± 0.04B
LVIDd (mm) 0 3.49 ± 0.35 3.36 ± 0.39 2.87 ± 0.16 2.94 ± 0.44
LVIDd (mm) 1 3.58 ± 0.45 3.61 ± 0.30 3.14 ± 0.17 3.08 ± 0.17
LVIDd (mm) 2 3.42 ± 0.24 3.24 ± 0.28 3.08 ± 0.42 2.95 ± 0.44
LVIDd (mm) 4 3.48 ± 0.41 4.06 ± 0.43A 3.25 ± 0.32 3.38 ± 0.30B
LVIDs (mm) 0 1.87 ± 0.37 1.81 ± 0.35 1.48 ± 0.16 1.49 ± 0.34
LVIDs (mm) 1 1.83 ± 0.42 2.00 ± 0.21 1.69 ± 0.14 1.69 ± 0.15
LVIDs (mm) 2 1.74 ± 0.24 1.72 ± 0.24 1.49 ± 0.33 1.57 ± 0.32
LVIDs (mm) 4 1.84 ± 0.35 3.01 ± 0.59A 1.71 ± 0.27 1.81 ± 0.25B
LVFS (%) 0 46.6 ± 6.7 46.1 ± 7.2 48.4 ± 4.7 49.7 ± 5.5
LVFS (%) 1 49.1 ± 6.9 44.6 ± 4.7 46.1 ± 3.6 45.3 ± 4.4
LVFS (%) 2 49.1 ± 5.1 46.7 ± 8.5 51.9 ± 5.8 47.0 ± 5.4
LVFS (%) 4 47.4 ± 5.1 26.4 ± 8.0A 47.4 ± 4.5 46.7 ± 4.0B
n = 7 WT-Cre mice, n = 7 Mtor-cKO mice, n = 8 4E-BP1-KO mice, and n = 9 dKO mice. Measure-
ments are given as mean ± SD. AP < 0.05 versus WT-Cre mice; BP < 0.05 versus 4 weeks after TMX 
administration Mtor-cKO mice.
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Pressure overload cardiac hypertrophy. We used 2-month-old male mice. 
Pressure overload was obtained through transverse aortic arch constric-
tion under anesthesia, as described previously (55).
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